A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney
November 29, 2018
(Length of Conversation: 18 min)
Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies.
Biographies:
Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute
Alicia Morgans, MD, MPH
Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies.
Biographies:
Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute
Alicia Morgans, MD, MPH
Related Content:
12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer
STAMPEDE - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer
Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden
ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC
12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer
STAMPEDE - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer
Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden
ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC